Allogene, Servier present data from UCART19 phase 1 study

Allogene Therapeutic and Servier announced results from an updated analysis of pooled clinical data from two ongoing Phase 1 studies of UCART19, the first allogeneic CAR T-cell therapy in clinical study, in pediatric and adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. The analysis showed that 82% of patients who received a lymphodepletion regimen consisting of fludarabine, cyclophosphamide and an anti-CD52 mAb achieved a complete remission or complete remission with incomplete blood recovery. In the four patients who received fludarabine and cyclophosphamide only, there was minimal UCART19 expansion and no response. Overall, 67% or 14/21 of patients achieved a CR/CRi. These data suggest an anti-CD52 antibody is an important addition to the lymphodepletion regimen for allogeneic CAR T cell expansion. The most common adverse events were related to cytokine release syndrome and were generally manageable.
https://thefly.com/landingPageNews.php?id=2831633